풀겐트 유전학즈(FLGT) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

FLGT

Fulgent Genetics Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$19.58

-0.09 ▼ -0.46%

🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)

$19.58

+0.00 +0.00%

풀겐트 유전학즈(FLGT) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$556M

스몰캡

P/E

배당수익률

없음

52주 위치

35%

저점 +45% · 고점 -37%

애널리스트

보유

Fundamental health

vs. Diagnostics & Research· based on 3 axes

수익성

산출 불가 (적자)

성장

Top 78%

밸류에이션

Top 87%

재무 안정

Top 44%

💰 Is this stock pricier than usual right now?

Compared to this company's own recent 2년 (not other companies).

Very cheap

Cheap

Typical

Pricey

🔥 Very pricey

Simply put — what you pay today to own $1 of this company's yearly earnings is 6원. Over the past 2년, it usually traded around 4원. One of the priciest stretches of the past 2년.

Pricy doesn't mean bad — it means expectations are already baked in.· based on 1.7 profitable years

Index ⓘ	RUT	P/E ⓘ	-	EPS (ttm) ⓘ	-2.4	Insider Own ⓘ	36.08%	Shs Outstand ⓘ	28.9M	Perf Week ⓘ	-0.15%
Market Cap ⓘ	0.56B	Forward P/E ⓘ	-	EPS next Y ⓘ	25.81%	Insider Trans ⓘ	-0.06%	Shs Float ⓘ	18.1M	Perf Month ⓘ	0.72%
Enterprise Value ⓘ	0.28B	PEG ⓘ	-	EPS next Q ⓘ	-0.46	Inst Own ⓘ	61.96%	Short Float ⓘ	15.17%	Perf Quarter ⓘ	20.05%
Income ⓘ	-0.07B	P/S ⓘ	1.74	EPS this Y ⓘ	-469.05%	Inst Trans ⓘ	-3.45%	Short Ratio ⓘ	6.37	Perf Half Y ⓘ	-29.62%
Sales ⓘ	0.32B	P/B ⓘ	0.54	EPS next 5Y ⓘ	-	ROA ⓘ	-6.25%	Short Interest ⓘ	2.75M	Perf YTD ⓘ	-25.47%
Book/sh ⓘ	36.39	P/C ⓘ	2.01	EPS past 3/5Y ⓘ	-	ROE ⓘ	-6.78%	52W High ⓘ	-36.92% ($31.04)	Perf Year ⓘ	6.59%
Cash/sh ⓘ	9.73	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	-19.52% -5.21%	ROIC ⓘ	-6.98%	52W Low ⓘ	45.47% ($13.46)	Perf 3Y ⓘ	-48.34%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	-79.16%	Gross Margin ⓘ	36.19%	Volatility(W/M) ⓘ	3.26% 3.3%	Perf 5Y ⓘ	-78.88%
Dividend TTM ⓘ	-	EV/Sales ⓘ	0.89	Sales Y/Y TTM ⓘ	9.54%	Oper. Margin ⓘ	-32.12%	ATR (14) ⓘ	0.67	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	5.31	EPS Q/Q ⓘ	-114.95%	Profit Margin ⓘ	-23.04%	RSI (14) ⓘ	48.15	Recom ⓘ	3
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	5.31	Sales Q/Q ⓘ	-3.16%	SMA20 ⓘ	-4.02% ($20.4)	Beta ⓘ	0.89	Target Price ⓘ	$15
Payout ⓘ	-	Debt/Eq ⓘ	0.01	Earnings ⓘ	2026/7/30	SMA50 ⓘ	3.28% ($18.96)	Rel Volume ⓘ	0.51	Prev Close ⓘ	$19.67
Employees ⓘ	1344	LT Debt/Eq ⓘ	0.01	EPS/Sales Surpr. ⓘ	-3.39% 4.47%	SMA200 ⓘ	-8.66% ($21.44)	Avg Volume(3M) ⓘ	0.43M	Price ⓘ	$19.58
IPO ⓘ	2016/9/29	Option/Short ⓘ	Yes/Yes			Trades ⓘ	6219	Volume ⓘ	221,339	Change ⓘ	-0.46%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $71M (YoY -3%) · 순이익 $-25M (YoY -115%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Fulgent Genetics Inc (FLGT) Investment Analysis

What kind of company is Fulgent Genetics Inc?

풀겐트 유전학즈(FLGT) 방어주

Healthcare · Diagnostics & Research

Healthcare Stocks

🧬 Fulgent Genetics (FLGT) is a U.S. diagnostics and testing company with genetic testing at its core. It offers a broad range of genetic diagnostic services using its proprietary technology platform, and has recently been expanding into the therapeutics segment by developing new anticancer drugs. Its defining feature is this dual structure that combines diagnostics with new drug development.

Learn more about Fulgent Genetics Inc →

Market Cap

$0.6B

Approx. KRW 0.8 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank3114

Employees1,344people

IPO2016/09/29

Current Price$19.58 ≈ 26,825원

📌 RUT · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release D-2

7월 30일 (목) · 장 마감 후

예상 매출 - · EPS $-0.44

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 1일 (금) · 장 시작 전 EPS -3.4% 매출 +4.5%

🔔 Earnings release 2026년 2월 27일 (금) · 장 시작 전

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

-32.1%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Net Margin

Share of revenue left after taxes and interest are paid

-23.0%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

36.2%

✓ 평균

My positionMid-range

Low range Average High range

Diagnostics & Research Median 52.1% · Bottom 34%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-6.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-6.3%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-7.0%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.01

✓ Very low debt

My positionTop 5%

Low range Average High range

Diagnostics & Research Median 0.38

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

5.31

✓ 우수

My positionTop 25%

Low range Average High range

Diagnostics & Research Median 2.23

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

5.31

✓ 우수

My positionTop 25%

Low range Average High range

Diagnostics & Research Median 2.15

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$15.00

현재가 대비 -23.4%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

내년 EPS 예상 성장률

+25.8%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Mixed beats and misses

예상 상회

예상 부합

예상 하회

50%

상회 비율

+216.5%

평균 서프라이즈

2026.05.01

하회

실적 $-0.36 · 예상 $-0.35 -3.4%

2026.02.27

상회

실적 $0.16 · 예상 $0.03 +436.4%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Concerns

Growth is lagging the industry average

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

-469.1%

매우 부진

My positionBottom 5%

Low range Average High range

방어주 소형주 Median 4.7% · Bottom tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+25.8%

양호

My positionMid-range

Low range Average High range

방어주 소형주 Median 10.1% · Top 37%

📊 How much has it grown? (actual results)

Past 5-Year Revenue

How much revenue grew over the past 5 years

-5.2%

매우 부진

My positionBottom 5%

Low range Average High range

방어주 소형주 Median 6.7% · Bottom tier

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-3.2%

부진

My positionBottom 25%

Low range Average High range

방어주 소형주 Median 4.9% · Bottom 25%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -147%p below the market

FLGT -78.9% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-147.2%p

Significantly behind the market

vs Health Care (XLV)

-103.4%p

Significantly behind the sector average

1-year basis

vs S&P 500

-9.4%p

slightly behind the market

vs Health Care (XLV)

-13.1%p

behind the sector average

Current position within 52-week range

Low (-45.5%p) High (-36.9%p)

Current price is 45.5% above the 52-week low and 36.9% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-46.0%

Annualized volatility

82.5%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-27

Downtrend zone

Current price $19.58 below the midline ($20.40). Normal downward flow. Inside the Ichimoku cloud (neutral).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-27

Neutral zone — weak trend

MACD 0.195 · Signal 0.415 · Hist -0.221. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-27

Bearish zone

RSI 48.1 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 16.4.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Assets·Vs. Sales

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🏢 Vs. Assets Cheap

🧾 Vs. Sales Cheap

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

0.54x

✓ Very cheap

My positionTop 5%

Low range Average High range

Diagnostics & Research median 3.37x · Top 1% — relatively cheap within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

1.74x

✓ Very cheap

My positionTop 25%

Low range Average High range

Diagnostics & Research median 4.06x · Top 25% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

Analyst target price (reference)

$15.00 vs. current price -23.4%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Diagnostics & Research

Who owns it?

Ownership backdrop is unfavorable

Insider modest net selling -0.1% · Institutional net selling -3.5% · Short interest elevated 15.2% · Short interest up +7.5pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-0.1%

Insiders little change

🏦 Institutions (funds & investors)

-3.5%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 62.0%

Adequate institutional weight

Healthcare 소형주 Median 65.6%

🧑‍💼 Insiders 36.1%

Founder/management large holders (strong skin-in-the-game)

Healthcare 소형주 Median 17.6%

👤 Retail investors (estimated) 2.0%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

15.2%

Somewhat high

Healthcare 소형주 Median 11.2%

Past 90 days 📈 +7.5%p increase

Short interest days to cover

6.4 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 28.9M주

Float (tradable shares) 18.1M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding FLGT

ETFs with the highest weightings · 10 total shown

XHS

State Street SPDR S&P Health Care Services ETF

0.81%

$206M

FFLS

The Future Fund Long/Short ETF

0.73%

$42M

BTR

Beacon Tactical Risk ETF

0.73%

$33M

SBIO

ALPS Medical Breakthroughs ETF

0.31%

$202M

SVAL

iShares US Small Cap Value Factor ETF

0.28%

$199M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
FLGT This Stock	$556.1M	-	0.5 ▲	-6.78% ▲	-	-0.5%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 풀겐트 유전학즈(FLGT)?

풀겐트 유전학즈(FLGT) belongs to the Healthcare sector and operates in the Diagnostics & Research industry.

What is the market cap of FLGT?

The market cap of FLGT is approximately $556M, ranking 3,114 within its sector.

What is the 52-week high and low for FLGT?

FLGT has recorded a 52-week high of $31.04 and a low of $13.46.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.